Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
How Does The Market Size Of The Neurotrophic Keratitis Treatment Industry Compare Between 2025 And 2029?
The neurotrophic keratitis treatment market has experienced significant expansion in recent years. Its value is expected to increase from $1.08 billion in 2024 to $1.47 billion in 2025, reflecting a compound annual growth rate (CAGR) of 36.3%. This historical growth can be attributed to factors such as a rise in diagnoses, an increase in injury and surgical procedures, growing research and development, and improvements in global healthcare infrastructure.
The neurotrophic keratitis treatment market is projected to experience substantial expansion in the coming years. Its size is anticipated to reach $4.99 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 35.9%. This growth throughout the forecast period is primarily attributed to educational initiatives, an increase in clinical trials, the development of advanced therapies, and favorable regulatory approvals. Key trends influencing the market during this period include enhancements in diagnostic tools, the integration of digital health solutions, novel neuroprotection strategies, and advancements in ocular surface imaging.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12968&type=smp
Which Industry Drivers Are Expected To Accelerate The Neurotrophic Keratitis Treatment Market From 2025 To 2029?
The increasing incidence of eye ailments is projected to boost the expansion of the neurotrophic keratitis treatment market in the future. These conditions encompass various medical issues and disorders impacting the eyes’ structure and functionality. Neurotrophic keratitis treatment offers benefits such as enhancing corneal sensation, fostering healing, preventing infections, and alleviating pain and discomfort. For example, reports from Eye Care One, a US-based eyecare career development services platform, indicated in March 2022 that an estimated 35 million US people would experience dry eye disease (DED) in 2022, with its prevalence expected to increase annually. Additionally, the Centers for Disease Control and Prevention, a US federal agency, reported in May 2024 that more than 3.4 million Americans aged 40 years and older are blind or visually impaired, a figure anticipated to double by 2030. Consequently, the rising occurrence of eye diseases is a key factor propelling the expansion of the neurotrophic keratitis treatment market.
What Are The Major Segment Types Covered In The Neurotrophic Keratitis Treatment Market?
The neurotrophic keratitis treatmentmarket covered in this report is segmented –
1) By Treatment: Topical Antibiotics; Recombinant Human Nerve Growth Factor (rhNGF); Amniotic Membrane Transplantation; Keratoplasty; Other Treatments
2) By Route of Administration: Oral; Topical; Other Routes of Administration
3) By Application: Stage I; Stage II; Stage III
4) By End-User: Hospitals; Homecare; Specialty Clinics; Other End-Users
Subsegments:
1) By Topical Antibiotics: Broad-Spectrum Antibiotics; Narrow-Spectrum Antibiotics
2) By Recombinant Human Nerve Growth Factor (rhNGF): Cenegermin Ophthalmic Solution; Other rhNGF-Based Solutions
3) By Amniotic Membrane Transplantation: Cryopreserved Amniotic Membrane; Dehydrated Amniotic Membrane
4) By Keratoplasty: Penetrating Keratoplasty; Lamellar Keratoplasty
5) By Other Treatments: Tarsorrhaphy; Therapeutic Contact Lenses
Which Trends Are Impacting The Neurotrophic Keratitis Treatment Market?
Leading companies within the neurotrophic keratitis treatment market are actively developing and obtaining approval for new drugs to sustain their standing. The development of new medications is essential in treating neurotrophic keratitis due to the current limited treatment options and the strong demand for more efficacious therapies to prevent the disease from advancing. For instance, in December 2022, BRIM Biotechnology Inc., a Taiwan-based clinical-stage firm, received Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for BRM424, targeting the treatment of neurotrophic keratitis (NK). BRM424 is a recombinant form of human nerve growth factor designed to stimulate the proliferation and differentiation of corneal limbal stem cells, thereby helping to regenerate and restore the cornea’s health in patients afflicted with neurotrophic keratitis.
Which Leading Companies Dominate The Neurotrophic Keratitis Treatment Market Share?
Major companies operating in the neurotrophic keratitis treatment market are Eyevance Pharmaceuticals LLC, Grand Pharma Co. Ltd., Walgreen Co., Pfizer Inc., Johnson and Johnson, Bayer AG, Novartis AG, Abbott Laboratories, Gilead Biosciences Inc., Merck and Co. Inc., Allergan Inc., Alcon Inc., Bausch Health Companies Inc., Bausch & Lomb Inc., CooperVision Inc., Rohto Pharmaceutical Co. Ltd., Santen Pharmaceutical Co. Ltd., Zhejiang Conba Pharmaceutical Co. Ltd., Glenmark Pharmaceuticals Limited, Dompe farmaceutici S.p.A, Aurolab, Ocular Therapeutix Inc., Laboratoires Thea SAS, Leadiant Biosciences Inc., ReGenTree LLC, Contacare Opthalmic Private Limited, Neuroptika Inc., Surgitech Innovation Private Limited.
Download The Full Report For Exclusive Market Findings:
What Are The Regional Market Dynamics Impacting The Neurotrophic Keratitis Treatment Industry?
North America was the largest region in the neurotrophic keratitis treatment market in 2024. The regions covered in neurotrophic keratitis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Request A Customized Version Of The Neurotrophic Keratitis Treatment Market Report:
https://www.thebusinessresearchcompany.com/customise?id=12968&type=smp
Browse Through More Reports Similar to the Global Neurotrophic Keratitis Treatment Market 2025, By The Business Research Company
Dry Eye Medication Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/dry-eye-medication-global-market-report
Newborn Eye Imaging Systems Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/newborn-eye-imaging-systems-global-market-report
Dry Eye Syndrome Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/dry-eye-syndrome-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model